Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0Q6CM)

Drug Name
CIGB-300 Drug Info
Synonyms P15; IGBC-300; P15-Tat
Indication
Disease Entry ICD 11 Status REF
Cervical cancer 2C77.0 Phase 3 [1]
Cross-matching ID
PubChem CID
86290205
ChEBI ID
CHEBI:83696
TTD Drug ID
DM0Q6CM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Casein kinase II (CSNK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CX-4945 DMWE7B9 Coronavirus infection 1D92 Phase 2 [2]
Tetrabromocinnamic acid DMKLIXZ Discovery agent N.A. Investigative [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Casein kinase II (CSNK2) TTZ5NI7 NOUNIPROTAC Modulator [1]

References

1 Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944.
2 CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.
3 Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39.